Judge Schedules Bellwether Trials for 2014 in Pradaxa MDL

With at least 131 cases filed across 19 jurisdictions in the Pradaxa Multi-District Litigation (MDL), U.S. District Judge David Herndon issued the schedule for four "bellwether" trials to start in August 2014 and end in early 2015.

Of those cases, 120 have been filed in the U.S. District Court for the Southern District of Illinois and 11 have been filed in state courts in California, Connecticut, and Illinois, reports The Madison-St. Clair Record.

Herndon also laid down some basic guidelines for filing procedures, depositions, and expert witnesses related to the Pradaxa MDL.

The orders relating to the Pradaxa MDL were issued on Oct. 3, in the presence of nearly a dozen lawyers who participated in the initial conference for the litigation in East St. Louis, reports The Record.

Pradaxa is a blood-thinning medication manufactured by Boehringer Ingelheim Pharmaceuticals that is used for the prevention of strokes, typically in patients with atrial fibrillation or irregular heartbeat.

It is alleged in the lawsuits that the manufacturers failed to warn users of the risks associated with the drug, including the potential for bleeding, and the lack of a known reversal agent to counteract its anti-coagulation property, writes The Record.

If you or a loved one has been harmed by Pradaxa or another dangerous drug, contact Sokolove Law today for a free legal consultation and to find out if a dangerous drug lawyer may be able to help you.

Tags: